A
Alcista
Alcista · 25%GTBP
$2.28
Precio del escenario
$4.440
-0.098 (-2.20%)Al cierre
Loading chart…
- Máximo
- 4.650
- Apertura
- 4.530
- Precio medio ponderado por volumen
- 4.43
- Volumen
- 50.47K
- Capitalización
- 6.08M
- Mínimo
- 4.210
- Importe
- 223.76K
- EV/EBITDA, TTM
- 0.00
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Análisis de IA of GT Biopharma Inc (GTBP)
VenderGT Biopharma Inc is not a good buy right now due to a significant net loss of $28.4 million for FY2025 and a current RSI of 23.39, indicating oversold conditions but also potential ongoing weakness. The stock has dropped 78.26% year-to-date, reflecting severe market challenges and investor sentiment issues.
Métricas de valoración
El PER previsto actual de GT Biopharma Inc (GTBP) es 17.33, frente a su media de 5 años de 1.45.
Escenarios de precio de Alphio AI para GTBP
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.507-06PRnewswireGT Biopharma Integrates AI to Accelerate Drug Development
8.506-12GlobenewswireGT Biopharma Advances NK Cell Therapy with TriKE Platform
8.506-12NewsfilterGT Biopharma Advances NK Cell Therapy with TriKE Platform
- 8.506-08Globenewswire
GT Biopharma Advances Three Drug Candidates into Clinical Trials
- 9.006-08Newsfilter
GT Biopharma Advances Three Cancer Drug Candidates into Clinical Trials
Preguntas frecuentes sobre GTBP, respondidas por Alphio AI
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
GT Biopharma Inc is not a good buy right now due to a significant net loss of $28.4 million for FY2025 and a current RSI of 23.39, indicating oversold conditions but also potential ongoing weakness. The stock has dropped 78.26% year-to-date, reflecting severe market challenges and investor sentiment issues.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarArtículos relacionados
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.